Using Qube 384, we profiled a panel of NaV inhibitors across species, providing valuable translational insight early in analgesic drug discovery.

We explore hNav1.9's unique fast and slow inactivation properties using Qube 384 and QPatch 48 platforms, helping to build more predictive screening assays for state-dependent inhibitors.

Reliable, high-throughput KV7 assays paired with expert interpretation enable faster progression of pain and epilepsy drug discovery programmes.

By accurately defining the drug exposure levels that affect QRS duration, researchers can establish safety margins, prioritise lower-risk compounds, and reduce the chance of late-stage failures due to cardiac toxicity

By accurately defining the drug exposure levels that affect QRS duration, researchers can establish safety margins, prioritise lower-risk compounds, and reduce the chance of late-stage failures due to cardiac toxicity

Enhance the predictive accuracy of cardiac safety assessments to ensure safer drug development and reduce the likelihood of late-stage failures due to cardiac toxicity

Highly-validated screening assays developed by Metrion are capable of confidently identifying modulators of the lysosomal TRPML1 channel.

Improve efficiency, reduce late-stage failures, and align with regulatory standards by assessing the proarrhythmic liability of your compounds early.

The ability to achieve patch-clamp-equivalent data quality using VSD enhances predictive accuracy, reducing false negatives and late-stage failures, and supports safer drug development with improved preclinical-to-clinical translation.

Achieve action potential recordings from intrinsically paced hiPSC-CMs with Metrion’s clinically predictive hiPSC cardiomyocyte assay.